Literature DB >> 22520146

Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.

Melanie Philippon1, Isabelle Morange, Marilyne Barrie, Anne Barlier, David Taieb, Henry Dufour, Bernard Conte-Devolx, Thierry Brue, Frédéric Castinetti.   

Abstract

We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal. Initial presentation was pituitary apoplexy leading to surgery. Dopamine agonists and radiotherapy allowed control of prolactin secretion and pituitary remnant. Metastasis appeared 10 years after initial presentation, leading to the diagnosis of pituitary carcinoma. At that time, dopamine agonists were no more effective; temozolomide, an oral alkylating agent, was administered for 24 cycles, and allowed decrease of the volume of the pituitary lesion and metastases. The patient is still currently followed in our department, 3 years after temozolomide withdrawal: prolactin level and pituitary tumor volume remain controlled without any chemotherapy. To our knowledge, this is the first case of MEN1 prolactin secreting pituitary carcinoma controlled long-term after temozolomide discontinuation.
Copyright © 2012. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22520146     DOI: 10.1016/j.ando.2012.03.001

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  6 in total

Review 1.  Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.

Authors:  Akira Matsuno; Mineko Murakami; Katsumi Hoya; Shoko M Yamada; Shinya Miyamoto; So Yamada; Jae-Hyun Son; Hajime Nishido; Fuyuaki Ide; Hiroshi Nagashima; Mutsumi Sugaya; Toshio Hirohata; Akiko Mizutani; Hiroko Okinaga; Yudo Ishii; Shigeyuki Tahara; Akira Teramoto; R Yoshiyuki Osamura
Journal:  Med Mol Morphol       Date:  2013-08-17       Impact factor: 2.309

2.  Prolactin-Secreting Pituitary Carcinoma with Dural Metastasis: Diagnosis, Treatment, and Future Directions.

Authors:  Justin Seltzer; John D Carmichael; Deborah Commins; Chia-Shang Jason Liu; Emily Omura; Eric Chang; Gabriel Zada
Journal:  World Neurosurg       Date:  2016-05-06       Impact factor: 2.104

3.  Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1.

Authors:  Hoong-Wei Gan; Chloe Bulwer; Owase Jeelani; Michael Alan Levine; Márta Korbonits; Helen Alexandra Spoudeas
Journal:  Int J Pediatr Endocrinol       Date:  2015-07-15

4.  Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina.

Authors:  Oscar D Bruno; Lea Juárez-Allen; Silvia B Christiansen; Marcos Manavela; Karina Danilowicz; Carlos Vigovich; Reynaldo M Gómez
Journal:  Int J Endocrinol       Date:  2015-05-27       Impact factor: 3.257

Review 5.  Phenotypes Associated With MEN1 Syndrome: A Focus on Genotype-Phenotype Correlations.

Authors:  Chiara Mele; Monica Mencarelli; Marina Caputo; Stefania Mai; Loredana Pagano; Gianluca Aimaretti; Massimo Scacchi; Alberto Falchetti; Paolo Marzullo
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-18       Impact factor: 5.555

6.  Pituitary carcinomas: Rare and challenging.

Authors:  Georges Sinclair; Martin Olsson; Hamza Benmakhlouf; Yahya Al-Saffar; Philippa Johnstone; Mustafa Aziz Hatiboglu; Alia Shamikh
Journal:  Surg Neurol Int       Date:  2019-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.